Institute of Gene Biology , Russian Academy of Science, 34/5 Vavilov str., 119334 Moscow, Russia.
Center for Data-Intensive Biomedicine and Biotechnology, Skolkovo Institute of Science and Technology , 3 Nobel str., 143026 Moscow, Russia.
J Am Chem Soc. 2017 Nov 15;139(45):16178-16187. doi: 10.1021/jacs.7b07118. Epub 2017 Oct 31.
Microcin C is a heptapeptide-adenylate antibiotic produced by some strains of Escherichia coli. Its peptide part is responsible for facilitated transport inside sensitive cells where it is proteolyzed with release of a toxic warhead-a nonhydrolyzable aspartamidyl-adenylate, which inhibits aspartyl-tRNA synthetase. Recently, a microcin C homologue from Bacillus amyloliquefaciens containing a longer peptide part modified with carboxymethyl-cytosine instead of adenosine was described, but no biological activity of this compound was revealed. Here, we characterize modified peptide-cytidylate from Yersinia pseudotuberculosis. As reported for B. amyloliquefaciens homologue, the initially synthesized compound contains a long peptide that is biologically inactive. This compound is subjected to endoproteolytic processing inside producing cells by the evolutionary conserved TldD/E protease. As a result, an 11-amino acid long peptide with C-terminal modified cytosine residue is produced. This compound is exported outside the producing cell and is bioactive, inhibiting sensitive cells in the same way as E. coli microcin C. Proteolytic processing inside producing cells is a novel strategy of peptide-nucleotide antibiotics biosynthesis that may help control production levels and avoid toxicity to the producer.
微菌素 C 是一种由某些大肠杆菌菌株产生的七肽-腺苷酸抗生素。其肽部分负责在敏感细胞内进行易位运输,在敏感细胞内,它被蛋白水解,释放出一个有毒的弹头——非水解的天冬氨酰-腺苷酸,从而抑制天冬氨酰-tRNA 合成酶。最近,描述了一种来自解淀粉芽孢杆菌的微菌素 C 同源物,它含有经过羧甲基胞嘧啶修饰的更长的肽部分,而不是腺苷,但这种化合物没有表现出生物活性。在这里,我们对来自假结核耶尔森氏菌的修饰肽-胞苷进行了表征。与 B. amyloliquefaciens 同源物报道的情况一样,最初合成的化合物含有一个长肽,其没有生物活性。该化合物在产生细胞内通过进化保守的 TldD/E 蛋白酶进行内切蛋白酶处理。结果,产生了一个含有 C 末端修饰胞嘧啶残基的 11 个氨基酸长的肽。该化合物被运出产生细胞,并具有生物活性,以与大肠杆菌微菌素 C 相同的方式抑制敏感细胞。在产生细胞内的蛋白水解处理是一种新型的肽核苷酸抗生素生物合成策略,可能有助于控制生产水平并避免对生产者的毒性。